Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models

URN to cite this document:: urn:nbn:de:bvb:355-epub-515258
DOI to cite this document:: 10.5283/epub.51525

Deng, Shanshan ; Solinas, Antonio

; Calvisi, Diego F.

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 27 Jan 2022 12:42

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide. Patients with early-stage HCC can be treated successfully with surgical resection or liver transplantation. However, the usual late diagnosis of HCC precludes curative treatments, and systemic therapies are the only viable option for inoperable patients. Sorafenib, an orally available multikinase ...